Next Article in Journal
Diffusion-Weighted MRI—The Way Forward for MRI in Myeloma?
Previous Article in Journal
Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
Previous Article in Special Issue
Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect
Review

Current Status of CAR-T Cell Therapy in Multiple Myeloma

Department of Hematology, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University Hospital Virgen del Rocio, Universidad de Sevilla, 41013 Sevilla, Spain
*
Author to whom correspondence should be addressed.
Academic Editors: Nicolaus Kröger and Laurent Garderet
Received: 30 July 2021 / Revised: 8 October 2021 / Accepted: 18 October 2021 / Published: 21 October 2021
Current data on CAR-T cell-based therapy is really promising in multiple myeloma, especially in terms of response. In heavily pretreated patients, who have already received proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, current trials report an overall response rate ranging from 81 to 97% and 45 to 67% of complete remission rates. Data are less encouraging in terms of duration of response, although most recent trials have shown significant improvements in terms of event-free survival, with medians ranging from 8 to 14 months and up to 77% progression-free survival at 12 months with an acceptable toxicity profile. These data will be consolidated in future years and will provide new evidence on the best timing for CAR-T cell therapy. Moreover, new CAR-T designs are underway and will challenge the current results. View Full-Text
Keywords: myeloma; CAR T-cells; target antigen myeloma; CAR T-cells; target antigen
MDPI and ACS Style

Reguera-Ortega, J.L.; García-Guerrero, E.; Pérez-Simón, J.A. Current Status of CAR-T Cell Therapy in Multiple Myeloma. Hemato 2021, 2, 660-671. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2040043

AMA Style

Reguera-Ortega JL, García-Guerrero E, Pérez-Simón JA. Current Status of CAR-T Cell Therapy in Multiple Myeloma. Hemato. 2021; 2(4):660-671. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2040043

Chicago/Turabian Style

Reguera-Ortega, Juan L., Estefanía García-Guerrero, and Jose A. Pérez-Simón 2021. "Current Status of CAR-T Cell Therapy in Multiple Myeloma" Hemato 2, no. 4: 660-671. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2040043

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop